Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus IFOSFAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus IFOSFAMIDE.
HEXALEN vs IFOSFAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Prodrug activated by cytochrome P450 to cytotoxic metabolites (4-hydroxyifosfamide, acrolein, and ifosforamide mustard) that alkylate DNA by cross-linking guanine bases, inhibiting DNA replication and transcription.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
1.2 g/m² IV over 2 hours daily for 5 consecutive days every 3 weeks, or 5 g/m² IV as a 24-hour continuous infusion every 3 weeks. Administer with mesna and vigorous hydration.
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Clinical Note
moderateIfosfamide + Digoxin
"Ifosfamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIfosfamide + Digitoxin
"Ifosfamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIfosfamide + Deslanoside
"Ifosfamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIfosfamide + Acetyldigitoxin
"Ifosfamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 4-7 hours for parent drug; active metabolite 4-desulfonate has half-life ~12-15 hours. Clinical context: Prolonged with renal impairment.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Primarily renal: 50-60% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Category C
Category D/X
Alkylating Agent
Alkylating Agent